Dupixent^® Lymphoma Risk

Does Dupixent Cause Lymphoma?

Dupixent, a drug used to treat conditions related to inflammation like eczema and asthma, has been connected to a higher risk of cutaneous T-cell lymphoma (CTCL).

CTCL is a type of blood cancer known as non-Hodgkin lymphoma. The cancer starts in T-cells, white blood cells that normally help the body fight infection. In CTCL, these cells become cancerous, multiply uncontrollably, and build up in the skin.

What you should know about CTCL:

• CTCL is rare, with the most common form affecting only about 1 in a million people in the U.S.
• CTCL most often appears between ages 50 and 60 but can develop at any age.
• You may be at higher risk if you’re a man, Black, or have a weakened immune system.
• Most forms of CTCL grow slowly. However, there is no cure, and like any cancer, CTCL can be fatal once it reaches advanced stages.
• Because CTCL symptoms can resemble psoriasis, eczema, or an allergic reaction, many people live with rashes, itching, or skin discoloration for years before they’re correctly diagnosed.
• Patients diagnosed in early stages have a 10-year survival rate of 90%, compared with 53% for those diagnosed in late stages, making early diagnosis critical.

Patients who developed CTCL after using Dupixent are filing legal claims against the drug’s makers, Regeneron Pharmaceuticals and Sanofi-Aventis, for failing to warn patients about the cancer risks.

At Sokolove Law, we’ve secured over $1.6 Billion for patients harmed by dangerous drugs and medical devices. If you’ve been diagnosed with CTCL, our attorneys may be able to seek compensation on your behalf.

Understanding How Dupixent Is Linked to Lymphoma

Dupixent was first approved by the U.S. Food and Drug Administration (FDA) in 2017 as a treatment for eczema. Since then, a growing body of research has connected the drug to cutaneous T-cell lymphoma.

Dupixent blocks immune system pathways, which may weaken the body’s ability to detect and control abnormal T-cells, per the journal Dermatitis. In March 2025, the FDA identified CTCL as a potential serious safety risk associated with Dupixent and began evaluating whether regulatory action was needed.

Key findings on how Dupixent is linked to lymphoma include:

• A study of 19,612 patients with eczema found Dupixent users were over 4.5 times more likely to be diagnosed with CTCL than non-users, per Dermatologic Therapy.
• Eczema patients who used Dupixent had a 310% increased risk of lymphoma compared to non-users, the Journal of the American Academy of Dermatology reported.
• Asthma patients using Dupixent faced a greater CTCL risk than patients treated with other medications, per the European Respiratory Journal.
• Dupixent users are at the highest risk of developing CTCL within 1 year of starting the drug, according to Dermatologic Therapy.

“Overall, we find that the use of dupilumab for treating atopic dermatitis is associated with an increased relative risk of developing CTCL. This risk is highest in the first year of therapy and in adult patients. These findings suggest exercising caution in treating select groups of patients with dupilumab.”
– Dermatologic Therapy

Victims who were diagnosed with CTCL after using Dupixent may be able to pursue legal claims against the drug’s manufacturers. Lawsuits can hold companies accountable for failing to warn about the risks of a prescription drug.

Types of CTCL and Dupixent Risks

The types of CTCL most often linked to Dupixent are mycosis fungoides and Sézary syndrome, according to Dermatologic Therapy.

However, there are many other, rarer forms of CTCL. Some progress slowly over many years, while others are aggressive and spread quickly.

Types of cutaneous T-cell lymphoma include:

• Mycosis fungoides: This is the most common type of CTCL. It typically grows slowly and usually stays in the skin, though cancerous cells can sometimes reach the lymph nodes and blood.
• Sézary syndrome: This fast-growing form of CTCL causes large numbers of cancerous T-cells to appear in both the skin and the bloodstream. It often causes discoloration across much of the body. Mycosis fungoides can progress into Sézary syndrome.
• Rare subtypes: Less common forms include primary cutaneous anaplastic large cell lymphoma, subcutaneous panniculitis-like T-cell lymphoma, and primary cutaneous gamma-delta T-cell lymphoma.

Some people may be more likely to develop CTCL because of risk factors like having a weakened immune system or being Black, a man, or over the age of 50. The risk for Dupixent patients is greatest during the first year of using the drug.

Patients diagnosed with any form of CTCL after using Dupixent may be entitled to seek compensation from the companies that put them in harm’s way.

Dupixent and T-Cell Lymphoma Symptoms

CTCL usually begins in the skin and may develop slowly for months or years, with symptoms changing over time. Early stages of CTCL and eczema can look nearly identical since both can cause red, dry, itchy, and scaly patches of skin.

Dupixent’s strong anti-inflammatory effects may mask early signs of CTCL. Eczema might appear to improve while cancerous T-cells continue to spread.

Common symptoms of cutaneous T-cell lymphoma include:

• Bumps on the skin that may break open
• Fatigue or unexplained weight loss
• Hair loss
• Itchy, rash-like discoloration spreading across the body
• Patches of discolored skin
• Raised rashes that may be flaky or itchy
• Swollen lymph nodes
• Thickened skin on the palms and soles of the feet

“At the time of my initial cancer diagnosis, I’d been getting treatment for years from a local dermatologist for chronic psoriasis. So, he’d already done many biopsies on me. But when an area of red skin also puffed up and started peeling, he performed another. That one showed a condition called mycosis fungoides, a type of skin cancer.”
– Karen, CTCL Survivor

If you use Dupixent and notice rashes that get worse or don’t respond to treatment, new patches or bumps, or swollen lymph nodes, talk to your doctor right away. Do not stop taking a prescribed medication without first consulting your doctor.

A doctor will review your medical history and examine any patches or thickened areas of skin. They may order biopsies, blood tests, and imaging to diagnose your condition.

Stages of Dupixent Cutaneous T-Cell Lymphoma

Doctors commonly identify the stages of CTCL by considering how much of the skin is affected, whether nearby lymph nodes are involved, and whether the cancer has spread to distant parts of the body.

The stages of CTCL include:

• Stage I: Bumps or red, scaly patches appear on the skin
• Stage II: Lymph nodes may be swollen, or at least 1 skin tumor may form
• Stage III: Discoloration covers most of the body
• Stage IV: Cancerous cells spread to the lymph nodes or may reach other organs such as the liver, lungs, or bone marrow

The cancer usually progresses through these stages slowly, and early treatment gives a patient the best chance of recovery. About 71.5% of patients with mycosis fungoides are diagnosed and treated while still in the early stages, per the International Archives of Allergy and Immunology.

Dupixent CTCL Treatment

You may receive a range of treatments for CTCL based on the type and stage of the cancer. Patients commonly receive medications like steroid ointments to manage skin symptoms as well as therapies like chemotherapy or radiation to kill cancer cells. Many patients need ongoing care for years.

The outlook for CTCL patients depends on how early it’s caught. About 90% of people diagnosed with early-stage (Stage I or II) CTCL are alive 10 years later, according to the Cleveland Clinic. For late-stage (Stage III or IV) CTCL, the 10-year survival rate drops to 53%.

Treatments for cutaneous T-cell lymphoma may include:

• Chemotherapy, which may be administered in pills, through a vein, or in a cream
• Extracorporeal photopheresis (ECP), which treats blood cells with light and then returns them to the body
• Immunotherapy to help your body’s own immune system fight cancer cells
• Light therapy (phototherapy), which shines light on the skin to kill cancer cells
• Radiation therapy, most commonly using X-rays or electrons on the skin
• Steroid creams or ointments to manage itching and rashes

These treatments can ease symptoms and slow the disease, and many people go into remission. However, doctors cannot currently cure CTCL.

The ongoing cost of care can place a serious financial burden on patients and families, but compensation from a Dupixent CTCL lawsuit may make the road ahead easier.

Can I File a Dupixent CTCL Lawsuit?

If you or a loved one was diagnosed with cutaneous T-cell lymphoma after using Dupixent, you may be able to pursue compensation from the drug’s manufacturers, Sanofi and Regeneron Pharmaceuticals, Inc.

Claims against the drugmakers accuse them of failing to warn patients about the cancer risk, which may have allowed CTCL to progress to more dangerous stages.

You may be eligible to file a Dupixent CTCL lawsuit if you or a loved one:

• Used Dupixent for eczema, asthma, or another condition
• Was later diagnosed with a type of CTCL, such as mycosis fungoides or Sézary syndrome
• Passed away from CTCL after using Dupixent

In July 2026, the U.S. Judicial Panel on Multidistrict Litigation centralized Dupixent CTCL lawsuits in the District of New Jersey, which allows similar legal claims to move forward together.

It’s important to act quickly. Each state has statutes of limitations, which set a deadline for filing lawsuits. If this date passes, you may lose your right to seek compensation. Contact a lawyer to understand what deadlines apply to your case.

Compensation for Cutaneous T-Cell Lymphoma and Dupixent

A CTCL diagnosis can lead to years of treatment, time away from work, and emotional strain. Filing a Dupixent lymphoma lawsuit may help you recover the money you need for your family’s future.

Compensation from a Dupixent CTCL lawsuit may help cover:

• Lost wages and reduced earning ability
• Pain and suffering
• Past and future medical bills
• Funeral and burial costs in wrongful death cases

Most dangerous drug cases are resolved through settlements. If your lawyer doesn’t reach a settlement with the drug companies, your case may go to trial.

Get Help from Our Dupixent CTCL Lawyers

If you developed cutaneous T-cell lymphoma after using Dupixent, you deserve answers and justice. At Sokolove Law, we can handle every step of your case so you can focus on your health and family.

With over 45 years of experience, Sokolove Law has recovered more than $1.6 Billion for clients harmed by dangerous drugs and medical devices.

You’ll pay no upfront costs or hourly fees to work with Dupixent CTCL lawyers at Sokolove Law. We only get paid if we recover compensation on your behalf.

Call (800) 995-1212 now or fill out our contact form to get started with a free, no-obligation case review.

Dupixent and Cutaneous T-Cell Lymphoma FAQs